Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,052 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R; TeraViC-4 Study Group. Sánchez-Tapias JM, et al. Among authors: crespo j. Gastroenterology. 2006 Aug;131(2):451-60. doi: 10.1053/j.gastro.2006.05.016. Gastroenterology. 2006. PMID: 16890599 Clinical Trial.
[Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis].
Buti M, Rodríguez Frías F, Calleja JL, Jardí R, Pons F, Crespo J, Casanovas T, Enríquez J, Carnicer F, Romero M, García Bengoechea M, Prieto M, García Samaniego J, Miras M, Pérez Roldán F, Rueda M, Esteban R. Buti M, et al. Among authors: crespo j. Med Clin (Barc). 2007 Oct 27;129(15):566-70. doi: 10.1157/13111710. Med Clin (Barc). 2007. PMID: 17988612 Clinical Trial. Spanish.
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Calleja JL, Pascasio JM, Ruiz-Antorán B, Gea F, Bárcena R, Larrubia JR, Pérez-Álvarez R, Sousa JM, Romero-Gómez M, Solá R, de la Revilla J, Crespo J, Navarro JM, Arenas JI, Delgado M, Fernández-Rodríguez CM, Planas R, Buti M, Forns X; Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis. Calleja JL, et al. Among authors: crespo j. Liver Int. 2015 Jan;35(1):90-100. doi: 10.1111/liv.12656. Epub 2014 Sep 15. Liver Int. 2015. PMID: 25113158 Clinical Trial.
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, Ouzan D, Maevskaya M, Calinas F, Morano LE, Crespo J, Dufour JF, Bourlière M, Agarwal K, Forton D, Schuchmann M, Zehnter E, Nishiguchi S, Omata M, Kukolj G, Datsenko Y, Garcia M, Scherer J, Quinson AM, Stern JO; STARTVerso1 Study Group. Ferenci P, et al. Among authors: crespo j. J Hepatol. 2015 Jun;62(6):1246-55. doi: 10.1016/j.jhep.2014.12.024. Epub 2015 Jan 2. J Hepatol. 2015. PMID: 25559324 Free article. Clinical Trial.
Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study.
Romero-Gómez M, Turnes J, Ampuero J, Oyagüez I, Cuenca B, Gonzalez-Garcia J, Muñoz-Molina B, Aguilar R, Leal S, Planas R, Garcia-Samaniego J, Diago M, Crespo J, Calleja JL, Casado MA, Sola R. Romero-Gómez M, et al. Among authors: crespo j. PLoS One. 2015 Mar 31;10(3):e0122613. doi: 10.1371/journal.pone.0122613. eCollection 2015. PLoS One. 2015. PMID: 25826755 Free PMC article.
1,052 results